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Objective: Hypertensive disorders in pregnancy are major causes of maternal mortality and morbidity.
Although the combined risk assessments of maternal history, blood pressure, uterine artery Doppler, and
maternal serum marker seem to be highly predictive of the development of hypertensive disorders, this
method is a little complicated to be performed on many low-risk pregnant women. The aim of this study
is to evaluate the use of maternal characteristics, and physical ﬁndings early in the second trimester, as
predictive factors of hypertensive disorders.
Materials and Methods: This is a retrospective cohort study undertaken in a single tertiary care center in
Japan. Singleton pregnant women without underlying disease and evaluated before 14 weeks of gesta-
tion were included. We conducted multivariate logistic regression analysis and decision tree analysis to
elucidate the potential risk factors of hypertensive disorders, including gestational hypertension and
preeclampsia.
Results: In total, 1986 women were evaluated, of whom 863 were nulliparous and 1123 were multipa-
rous, and 166 (8.3%) were diagnosed with hypertensive disorders. In multivariate analysis, maternal age
 40 years, prepregnancy BMI  30 kg/m2, in vitro fertilization and embryo transfer (IVF-ET), family
history of hypertension, and blood pressure  130/85 mmHg at ﬁrst visit were independent risk factors
for the nulliparous women. Maternal age  40 years, a history of previous hypertensive disorders, and
blood pressure  130/85 mmHg at ﬁrst visit were independent risk factors for the multiparous women.
According to the decision tree analysis, high-risk populations were as follows: women  40 years old
who conceived thorough IVF-ET and women with prepregnancy BMI  30 kg/m2 who conceived
spontaneously in nulliparous women; women with a history of hypertensive disorders and women with
blood pressure  130/85 mmHg in the absence of the previous history.
Conclusion: The combination of maternal background and physical ﬁndings is useful to identify the
population with a high risk of hypertensive disorders.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Hypertensive disorders complicate approximately 6e8% of all
pregnancies [1]. These pathological conditions consist of gesta-
tional hypertension (GH) and preeclampsia (PE), both of which are
major causes of maternal mortality and morbidity. They constitute, Osaka Medical Center and
1101, 840, Murodocho, Izumi,
mamoto).
bstetrics & Gynecology. Published b14% of the overall incidence of maternal death [2] and an estimated
50,000e60,000 PE cases are related to maternal deaths per year
worldwide [3]. Hypertensive disorders in pregnancy can cause se-
vere maternal complication such as HELLP (hemolysis, elevated
liver enzyme levels, and low platelet count) syndrome, neurological
and cerebral manifestations, and renal changes [4], which some-
times need early termination of pregnancy. GH is also related to
adverse pregnancy outcomes [5], and GH in some women possibly
progresses to PE [6]. Thus, pregnant women considered to be at
high risk of hypertensive disorders may need to be managed more
carefully for maternal and fetal conditions. In addition, the possi-
bility of low-dose aspirin (LDA) administration before 16 weeks ofy Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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shown [7e9]. Thus, identifying high-risk women during the early
period of pregnancy will be valuable for the prevention and certain
management of the aforementioned pregnancy complications.
Recent studies have demonstrated the value of risk assessment,
with the combination of obtaining information onmaternal history,
blood pressure, uterine artery Doppler, andmaternal serummarker
to determine the individual risk of hypertensive disorders in early
gestation [10e12]. Although these combinational assessments
seem to be highly predictive of the development of hypertensive
disorders, this method is a little complicated to be performed on
many low-risk pregnant women. With respect to the risk assess-
ment of hypertensive disorders with maternal baseline character-
istics, previous history of maternal hypertensive disease is a highly
predictive factor but is based on meta-analysis including nullipa-
rous women [13].
The aim of this study is to evaluate the use of maternal char-
acteristics, and physical ﬁndings early in the second trimester, as
predictive factors of hypertensive disorders. We elucidate the in-
dividual risk of hypertensive disorders without using uterine artery
Doppler ﬂow and maternal serum markers in each group of
nulliparous andmultiparous, healthy, singleton pregnantwomen in
a single cohort.
Materials and methods
This is a retrospective cohort study performed from January
2011 to December 2013 in the Osaka Medical Center and Research
Institute for Maternal and Child Health, Izumi, Japan. Singleton
pregnant women who visited our clinic before 14 weeks of gesta-
tion and delivered after 20 weeks of gestation were included. We
excluded patients with chronic diseases such as chronic hyper-
tension, diabetes mellitus, autoimmune disease, and chronic
nephritis.
All of the patients were asked to complete a questionnaire on
maternal age, racial origin, methods of conception, obstetric his-
tory, cigarette smoking during pregnancy, medical history, and
second-degree family history, including hypertension at their ﬁrst
visit. The questionnaire was reviewed by midwives and then
checked by obstetricians. Body mass index (BMI) was calculated by
dividing weight by the square of height. Urinary examination was
checked by using a dipstick. Blood pressure was measured in the
sitting position, using either arm, using an automated sphygmo-
manometer. Gestational age was conﬁrmed by the measurement of
the fetal crownerump length (CRL) on ultrasonography within the
period when the CRL ranges from 14 mm to 41 mm. Until 34 weeks
of gestation, the patients visited fortnightly, and after 35 weeks of
gestation, they visited weekly for a prenatal checkup. If the pa-
tient’s blood pressure was  140/90 mm Hg, self-monitoring of
blood pressure was prescribed. When hypertensive disorder was
suspected, admission for intensive maternal and fetal monitoring
was offered. During the hospital stay, the patients underwent blood
tests and measurement of 24-hour proteinuria accumulation to
conﬁrm the diagnosis and to rule out secondary hypertension.
Hypertensive disorders in pregnancy, including GH and PE, were
diagnosed according to the diagnostic criteria of the National High
Blood Pressure Education Program Working Group [1]. PE was
deﬁned by the development of new-onset hypertension with pro-
teinuria after 20 weeks of gestation, and GH was deﬁned as the
development of new-onset hypertension without proteinuria after
20 weeks of gestation and the normalization of blood pressure
levels by 12 weeks postpartum. The diagnostic threshold for hy-
pertensionwas a systolic blood pressure 140mmHg or a diastolic
blood pressure 90mmHg on two occasions at least 6 hours apart.
Proteinuriawas deﬁned as a protein excretion of 300mg/d from 24-hour urine collection. If there was only a dipstick available,
repeated semiquantitative test results of 1þ were considered as
positive.
The primary outcome was the development of hypertensive
disorders, including PE and GH. We reviewed maternal age (  40
years), BMI before pregnancy ( 30 kg/m2), in vitro fertilization and
embryo transfer (IVF-ET), smoking during pregnancy, family his-
tory of hypertension, and systolic blood pressure  130 mm Hg or
diastolic blood pressure  85 mm Hg at ﬁrst visit as potential
maternal risk factors. In multiparous women, a history of previous
hypertensive disorder in pregnancy was also reviewed. The prev-
alence of each risk factor was compared between the women with
and without hypertensive disorders during pregnancy. Nulliparous
and multiparous women were evaluated individually in order to
determine the value of data regarding the history of a previous
hypertensive disorder.
For statistical analysis, the Chi-square test was used for nominal
data, and the ManneWhitney U test was used for continuous data.
A p value< 0.05was considered statistically signiﬁcant.Multivariate
logistic regression analysiswith a step-up procedurewas conducted
to calculate the adjusted odds ratio (aOR) of risk factors with a
p value < 0.2 in the univariate analysis. In addition, we calculated
sensitivity, speciﬁcity, positive predictive value and negative
predictive value of each independent risk factor. Signiﬁcant risk
factors in themultivariate logistic regression analysiswere assessed
using the decision tree analysis to ﬁnd the high-risk combination of
the extracted factors. Each factorwasweighted due to the likelihood
ratio of developing hypertensive disorders by using the Chi-square
test, and optimized stratiﬁcation was automatically performed
according to the descending order of likelihood ratio. All the
statistical analyses were performed using the statistical software
package JMP 10 (SAS Institute Inc., Cary, NC, USA).
All the pregnant women provided written informed consent for
the provision of their information.
Results
In our hospital, 4489 women with singleton pregnancy deliv-
ered, of whom 2143 met the inclusion criteria. One hundred and
ﬁfty-sevenwomen had chronic diseases, including 32 with chronic
hypertension, 53 with autoimmune disease, nine with nephritis, 68
with prepregnancy diabetes mellitus, and ﬁve with overlapping
diseases. Finally, 1986 women were evaluated in the study, of
whom 863 were nulliparous and 1123 were multiparous.
The maternal demographic characteristics are shown in Table 1.
Maternal age, BMI before pregnancy, and the ﬁrst blood pressure
measurement of women with hypertensive disorders were signif-
icantly higher than those of the women without disorders in both
nulliparous and multiparous women. Multipara women with hy-
pertensive disorders had a more frequent history of hypertensive
disorders. Blood pressure data was lacking in 38 cases. In these
cases, the patient’s data was included in the analysis, excluding the
blood pressure.
One hundred and sixty-six women (8.3%) were diagnosed with
hypertensive disorders during pregnancy, including 116 with GH
(5.8%) and 50 with PE (2.6%). The incidence of all hypertensive
disorders, GH and PE were 10.2% (88), 6.1% (53), and 4.1% (35),
respectively, among the nulliparous women, and 6.9% (78), 5.6%
(63), and 1.3% (15) among the multiparous women. Among the
nulliparous women, maternal age  40 years [p ¼ 0.04, aOR 1.891,
95% conﬁdence interval (CI) 1.028e3.476], BMI before pregnancy 
30 kg/m2 (p < 0.01, aOR 3.869, 95% CI 1.546e9.686), IVF-ET
(p < 0.01, aOR 2.370, 95% CI 1.353e4.150), family history of hyper-
tension (p ¼ 0.036, aOR 1.666, 95% CI 1.033e2.686), and blood
pressure at ﬁrst visit (p ¼ 0.016, aOR 2.571, 95% CI 1.194e5.534)
Table 1







Maternal age (y) 36.0 (18e44) 32.0 (15e50) <0.01*
>40 y 20 (22.7) 79 (10.2) <0.01*
BMI before pregnancy 23.1 (16.6e35.5) 20.6 (14.5e42.9) <0.01*
BMI >30 8 (9.1) 21 (2.7) <0.01*
Smoking during pregnancy 2 (2.3) 37 (4.8) 0.407
Gestational wk at 1st BP measurement 11 (5e14) 10 (5e14) 0.219
Systolic BP 118.0 (90e148) 112.0 (71e145) <0.01*
Diastolic BP 72.0 (54e94) 66.0 (29e96) <0.01*






Multiparous women (n ¼ 1123)
Maternal age (y) 36.0 (25e44) 34.0 (17e47) <0.01*
>40 y 17 (21.7) 89 (8.5) <0.01*
BMI before pregnancy 22.3 (16.8e39.8) 20.8 (15.3e47.8) <0.01*
BMI >30 6 (7.7) 26 (2.5) <0.01*
Smoking during pregnancy 5 (6.4) 68 (6.5) 0.973
Gestational wk at 1st BP measurement 10 (6e14) 10 (4e14) 0.212
Systolic BP 119.0 (96e139) 112.0 (78e156) <0.01*
Diastolic BP 74.0 (48e92) 65.0 (33e95) <0.01*
BP >130/85mmHg at 1st BP measurement 12 (15.4) 26 (2.5) <0.01*
History of hypertensive disorder 18 (23.1) 38 (3.6) <0.01*
Data are shown as median (range) or n (%).
* p < 0.05, c2 test and ManneWhitney U test.
BMI ¼ body mass index; BP ¼ blood pressure.
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disorders in multivariate analysis (Table 2). Among the multiparous
women, the history of hypertensive disorders (p < 0.01, aOR 6.599,
95% CI 3.379e12.733), blood pressure  130/85 mm Hg at ﬁrst
booking (p < 0.01, aOR 5.796, 95% CI 2.812e11.945), and maternal
age  40 years (p ¼ 0.012, aOR 2.273, 95% CI 1.200e4.308) were
independently associated with the development of hypertensive
disorders (Table 3). Sensitivity, speciﬁcity, positive predictive value,
and negative predictive value of independent risk factors are shown
in Table 4.
According to the decision tree analysis, IVF-ET was the primary
factor to stratify nulliparous women.Women older than 40 years in
the IVF-ET group and womenwith a prepregnancy BMI higher than
30 kg/m2 in the non-IVF-ET group tended to develop the disorders
frequently (36% and 24%, respectively). The multiparous women
were primarily stratiﬁed according to the history of hypertensive
disorders. About one-third of the women with a history of hyper-
tensive disorders repeatedly developed the disorders during their
current pregnancies. In the absence of a previous history, the
incidence of the disorders among the women with blood pressure
 130/85 mm Hg was relatively high (24%; Figure 1).Table 2
Risk factors of hypertensive disorders during pregnancy in nulliparous women (n ¼ 863)
Values cOR (95% CI)
Maternal age  40 years 2.591 (1.495e4.492)
BMI before pregnancy  30 kg/m2 3.590 (1.540e8.369)
IVF-ET 3.059 (1.831e5.110)
BP  130/85 mm Hg 3.871 (1.906e7.861)
Smoking during pregnancy 0.463 (0.109e1.958)
Family history of HT 1.599 (1.012e2.254)
* p < 0.05. Univariate analysis and multivariate logistic regression analysis.
aOR ¼ adjusted odds ratio; BMI ¼ body mass index; BP ¼ blood pressure; cOR ¼ crude
NA ¼ not assessed.Discussion
In this study, we revealed the incidence of new-onset hyper-
tensive disorders among healthy singleton pregnant women who
consistently received prenatal care in a single center and demon-
strated the independent risk factors assessable in the ﬁrst trimester.
Our results indicate that for nulliparous women, the extracted risk
factors were older maternal age, high blood pressure at ﬁrst visit,
IVF, and family history of hypertension. Meanwhile, regarding the
multiparous women, older maternal age, high blood pressure, and
history of hypertensive disorders were recognized as independent
risk factors.
Although most of the previous studies discussed methods of
predicting PE [10e13], we primarily intended to predict hyper-
tensive disorders, including both PE and GH, because PE and GH
both cause severe maternal complications [14] and adverse preg-
nancy outcomes such as preterm birth, small for gestational age,
and neonatal hospital stay [5]. Hauth et al [14] showed that preg-
nant women with GH developed elevated levels of liver enzymes
and renal dysfunction more frequently than women without GH.
According to another study described by Villar et al [5], the aORs of.
p aOR (95% CI) p
<0.01* 1.893 (1.030e3.486) 0.040*
<0.01* 3.583 (1.451e8.846) <0.01*
<0.01* 2.374 (1.356e4.156) <0.01*
<0.01* 2.606 (1.213e5.598) 0.014*
0.219 NA NA
0.043* 1.671 (1.036e2.694) 0.035*
odds ratio; HT ¼ hypertension; IVF-ET ¼ in vitro fertilization and embryo transfer;
Table 3
Risk factors of hypertensive disorders during pregnancy in multiparous women (n ¼ 1123).
Values cOR (95% CI) p aOR (95% CI) p
Maternal age  40 y 2.994 (1.676e5.345) <0.01* 2.273 (1.200e4.308) 0.012*
BMI before pregnancy  30 kg/m2 3.266 (1.302e8.190) <0.01* 2.808 (0.944e7.237) 0.062
IVF-ET 2.654 (1.368e5.150) <0.01* 1.940 (0.864e4.026) 0.10
BP 130/85 mm Hg 6.896 (3.502e13.580) <0.01* 5.796 (2.812e11.945) <0.01*
Smoking during pregnancy 0.984 (0.384e2.516) 0.973 NA NA
Family history of HT 1.591 (0.982e2.579) 0.057 1.212 (0.693e2.057) 0.49
History of hypertensive disorder 7.950 (4.284e14.754) <0.01* 6.599 (3.379e12.733) <0.01*
* p < 0.05. Univariate analysis and multivariate logistic regression analysis
aOR ¼ adjusted odds ratio; BMI ¼ body mass index; BP ¼ blood pressure; cOR ¼ crude odds ratio; HT ¼ hypertension; IVF-ET ¼ in vitro fertilization and embryo transfer;
NA ¼ not assessed.
Table 4
Predictive value of independent risk factors of hypertensive disorders during
pregnancy.
Sensitivity Speciﬁcity PPV NPV
Nulliparous women
Maternal age  40 y 22.7 89.8 20.2 91.1
BMI before pregnancy  30 kg/m2 9.1 97.3 27.6 90.4
IVF-ET 28.4 88.5 21.9 91.6
BP  130/85 mm Hg 11.8 97.2 32.3 90.8
Family history of HT 38.6 71.7 13.4 91.1
Multiparous women
Maternal age  40 y 21.8 91.5 16.0 94.0
BP  130/85 mm Hg 15.6 97.5 31.6 93.9
History of hypertensive disorder 23.1 96.4 32.1 94.4
Data are shown as %.
BMI ¼ body mass index; BP ¼ blood pressure; HT ¼ hypertension;
IVF-ET ¼ in vitro fertilization and embryo transfer, NPV ¼ negative predictive
value; PPV ¼ positive predictive value.
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the PE group, and 1.6 and 1.2, respectively, in the GH group. They
concluded that both PE and GH signiﬁcantly increased the inci-
dence of adverse pregnancy outcomes. Therefore, the prediction
and risk assessment of both PE and GH are clinically meaningful for
perinatal management.
The antenatal care trial research of the World Health Organi-
zation conducted in some countries of South America and Asia
showed that the incidence of PE was 2.2% and that of gestational
hypertension was 7.0% among pregnant women, including those
with chronic complications [5]. The present study demonstrated
that the incidence rates of PE and GH were 2.6% and 5.8%, respec-
tively. This might be because women with chronic disease, who
were regarded as high risk for hypertensive disorders, were
excluded in our population. Among the nulliparous women, the
incidence of PE was 4.1%, which was similar to the incidence of 5.3%
in a prospective observational study of only nulliparous women
without any chronic complications [15]. Among the multiparousFigure 1. Decision tree analysis for the prediction of the hypertensive disorders. Decision tr
risk factors for prediction in each nulliparous and multiparous woman. BMI, body mass indwomen, Baschat et al [11] showed an incidence of PE of 3.1%. This
higher incidence could also be explained by the different study
participants, including any women with complications.
We evaluated the usefulness of maternal history and blood
pressure at booking as the simplest biophysical marker for the
prediction of hypertensive disease in pregnancy. The independent
risk factors found in our study were similar to those reported in
previous studies. The risk factors of PE at antenatal booking were
reviewed by Duckitt and Harrington D [13] in a systematic review.
They identiﬁed a previous history of PE [risk ratio (RR) 7.19], nul-
liparity (RR 2.91), family history of PE (RR 2.90), increased BMI
before pregnancy (RR 2.47), maternal age (RR 1.96), and increased
diastolic blood pressure  80 mm Hg at booking (RR 1.38) as the
affecting factors of PE. The presence of hypertensive disorders in
previous pregnancy was the most remarkable factor, as also shown
in our study. However, the estimated aOR of the previous PE in the
population included nulliparous women. It is certain that only
multiparous women have a history of hypertensive disorders in
pregnancy, so assessment of multiparous women only would be
adequate. Therefore, we evaluated the predictive value of a previ-
ous history of hypertensive disorders in a population restricted to
multiparous women. Meanwhile, nulliparous women may have
unrecognized risk factors such as any chronic diseases that cause
adverse pregnancy outcomes if they do not undergo medical
assessment. In addition, nulliparous women have been thought as
potentially at high risk because of immunological factors such as
ﬁrst exposure to paternal antigens [16]. Therefore, it might be
appropriate to separately estimate the risk of hypertensive disor-
ders among nulliparous and multiparous women. In our study, the
associated factors of the disorders among the multiparous women
were previous hypertensive disorders, blood pressure at ﬁrst
booking, and maternal age, while prepregnancy BMI data was not
collected. In the nulliparous women, prepregnancy BMI, blood
pressure at ﬁrst visit, IVF, maternal age, and family history of hy-
pertension were independent risk factors. Our study revealed the
difference in risk factors between nulliparous and multiparousee analysis for prediction of hypertensive disorders shows the valuable combination of
ex; BP, blood pressure; IVF-ET, in vitro fertilization and embryo transfer.
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healthy singleton pregnancies. In respect of predictive value, the
risk factors we have shown tend to have relatively high speciﬁcity
and negative predictive value, along with low sensitivity and pos-
itive predictive value, which means they might be helpful to
recognize patients with a lower risk of hypertensive disorders.
These ﬁndings were similar to the predictive values of algorithm
which comprise maternal characteristics, serum marker and uter-
ine artery Doppler in the previous report of North et al [17].
For blood pressure assessment, we focused on blood pressures
130/85 mm Hg, which is referred to as “highenormal blood pres-
sure” [18]. A previous study by Ohkuchi et al [19] on the prevalence
of PE and GH according to categorized BMI and blood pressure in
the second trimester demonstrated a higher incidence in women
with highenormal blood pressure or hypertension than in women
with normal blood pressure, after adjustment for BMI. Some
guidelines have already noted various ranges of blood pressure at a
stage prior to hypertension; for example, the clinical guidelines of
the Society of Obstetricians and Gynaecologists of Canada recom-
mend systolic blood pressure  130 mm Hg or diastolic blood
pressure  80 mmHg at booking as a risk marker of PE [20]. By
contrast, Cnossen et al [21] assessed the prediction ability of sys-
tolic, diastolic, mean arterial pressure, and their combination at the
ﬁrst and second trimesters for PE, and concluded that mean arterial
pressure in the low-risk group and diastolic BP in the high-risk
group at second trimester were the most valuable. Although
recent large-scale prospective studies have discussed the associa-
tion between mean blood pressure and the onset of diseases
[10,11], mean blood pressure seems inappropriate to use because it
needs to be calculated and may not be simple to apply to a large
population. Therefore, we considered highenormal blood pressure
at ﬁrst booking as the optimum option.
Recently, the signiﬁcance of ﬁrst-trimester screening of PE using
the combination of maternal background, blood pressure, and
maternal serummarkers, and assessment of uterine artery Doppler
ﬂow has been demonstrated [10e12]. As indicated in our study, a
clear prediction, especially in nulliparous women may, be difﬁcult.
Therefore, the aforementioned additional information is needed for
a more accurate prediction. However, maternal serummakers such
as pregnancy-associated plasma protein-A level are not measured
in routine prenatal care in some countries [22], as they are in our
institution. Moreover, uterine artery Doppler may be difﬁcult to
perform as a screening test for all pregnant women. It may be said
that screening with only maternal history and blood pressure at
ﬁrst visit is simple to apply for primary hospitals that are required
to examinemany low-risk pregnant women. Introducing additional
risk assessments and careful follow-up for populations found to be
at high risk in the simple assessment might be efﬁcient.
The strength of our study is that it evaluated a large cohort of
healthy singleton pregnant women who were managed uniformly
in a single center from early in the second trimester. In addition, we
separately calculated aOR for nulliparous and multiparous, and
revealed the difference between nulliparous and multiparous
women, thereby providing a more accurate risk estimation. In
addition, we carefully collected most of the data from individual
medical records to ensure data accuracy. One limitation of this
study is the missing data due to its retrospective design. The blood
pressure data of 38 women was missing, however, this number is
not large enough to affect the results. Another limitation was that
the use of LDAwas unscreened in this cohort. However, because we
did not prophylactically administer LDA even to the high-risk
population in this period, the number of women using LDA seems
small. LDA is now considered as a way of preventing PE [3]. In the
future, we should include the number and characteristics of pa-
tients using LDA and evaluate its effectiveness.In conclusion, we separately showed the maternal risk factors of
hypertensive disorders before the early stage of the second
trimester of pregnancy in nulliparous andmultiparous women. The
combination of background assessment and physical ﬁndings
might be useful as a simple way to identify the population with a
high risk of hypertensive disorders.
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